The selection of multiplexed testing techniques over multiple individual molecular aberrations' assessment offers the compelling advantage of interrogating multiple alterations from one sample.
Therefore, to track the causes of expression variations it is necessary to interrogate multiple types of molecular aberrations concurrently.
In recent years, multiple chromosomal and molecular aberrations have been discovered that contribute to the development of this disease.
In the case of circulating tumor cells and circulating tumor DNA, they may also serve as a noninvasive means of assessing molecular aberrations in tumors at multiple time points before and during therapy.
Our findings also demonstrate that stereotactic biopsy of the safest intracranial disease location offers bona fide representation of certain molecular aberrations, abrogating the need for multiple biopsies at different sites of primary or metastatic tumor to elucidate the molecular signature from which therapy may be informed.
The dependencies between molecular aberrations and gene expressions may be modular, as multiple genes with coherent expression profiles are likely to be affected by common molecular aberrations.
Dysregulation of multiple RTKs, including EGFR, FGFR1, and HGFR (also called c-Met) [ 3– 5], is one of the major molecular aberrations in BTBC.
Multiple gene alterations, including allelic deletion, insertion, polymorphism mutation, and methylation change, are marked in HCC, causing genetic and molecular aberrations.
Multiple mechanisms may be involved, including radiation resistance, partially through mechanisms involving the antioxidant defence systems as well as molecular aberrations at the genetic level.
